ID: ALA3957240

Max Phase: Preclinical

Molecular Formula: C19H17N5O2

Molecular Weight: 347.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  N#Cc1ccc(NC(=O)N2CCCc3cc(C4CC4)c(C=O)nc32)nc1

Standard InChI:  InChI=1S/C19H17N5O2/c20-9-12-3-6-17(21-10-12)23-19(26)24-7-1-2-14-8-15(13-4-5-13)16(11-25)22-18(14)24/h3,6,8,10-11,13H,1-2,4-5,7H2,(H,21,23,26)

Standard InChI Key:  IPZPDDMTAVNRHG-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 347.38

Molecular Weight (Monoisotopic): 347.1382

AlogP: 3.02

#Rotatable Bonds: 3

Polar Surface Area: 98.98

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.95

CX Basic pKa: 1.03

CX LogP: 3.25

CX LogD: 3.25

Aromatic Rings: 2

Heavy Atoms: 26

QED Weighted: 0.86

Np Likeness Score: -1.31

References

1.  (2016)  Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors, 

2. Fairhurst RA,Knoepfel T,Buschmann N,Leblanc C,Mah R,Todorov M,Nimsgern P,Ripoche S,Niklaus M,Warin N,Luu VH,Madoerin M,Wirth J,Graus-Porta D,Weiss A,Kiffe M,Wartmann M,Kinyamu-Akunda J,Sterker D,Stamm C,Adler F,Buhles A,Schadt H,Couttet P,Blank J,Galuba I,Trappe J,Voshol J,Ostermann N,Zou C,Berghausen J,Del Rio Espinola A,Jahnke W,Furet P.  (2020)  Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.,  63  (21.0): [PMID:32930584] [10.1021/acs.jmedchem.0c01019]

Source

Source(2):

• Scientific Literature
• BindingDB Database